Countdown Begins for Generic Ozempic Wave in India

Patent Expiry and Launch Timeline

Novo Nordisk’s patent protection for semaglutide expires on March 20, 2026, in India and several other countries. This triggers a wave of generic launches within weeks. More than two dozen generics are in the pipeline, with nearly 50 versions being developed across the industry.

Companies Preparing Launches

Leading Indian pharma firms including Dr Reddy’s Laboratories, Sun Pharmaceutical Industries, and Zydus Lifesciences are gearing up. Multiple brand names are being finalized. Dr Reddy’s plans to launch in India and export to other markets. Zydus will introduce generic semaglutide injections post-expiry.

Current Pricing and Expected Reduction

Rybelsus (oral) costs Rs 6,900–9,000 per month; Ozempic injection Rs 8,800–11,000; Wegovy Rs 11,850–26,050 depending on dose. Generic competition is expected to reduce prices by 60–70% initially, with further drops to 80–90% as production scales and competition intensifies.

Medical Uses and Market Impact

Semaglutide (GLP-1 therapy) regulates appetite, insulin, and digestion for type-2 diabetes and obesity management. India’s rising diabetes and obesity burden drives demand. The anti-obesity drug market (Rs 3,000–3,500 crore) is projected to grow nearly eightfold by 2030. Affordable generics could enable earlier use in treatment pathways and increase access for millions.

Expert Opinions

Dr Ankita Tiwari (Manipal Hospital Bhubaneswar): Lower-cost semaglutide will dramatically improve access to GLP-1 therapy where price has been a barrier.

Mumbai diabetologist: If generics match innovator quality, it could be a game-changer for disease-modifying therapy in India.

IN SHORTThe patent for semaglutide (active ingredient in Ozempic, Wegovy, Rybelsus) expires on March 20, 2026, in India. Over two dozen generic versions are set to launch soon from companies including Dr Reddy’s, Sun Pharma, and Zydus Lifesciences. Prices could drop 60–70% initially and up to 80–90% long-term, improving access for diabetes and obesity patients. The market for anti-obesity drugs in India is Rs 3,000–3,500 crore and expected to grow eightfold by 2030. Experts call it a game-changer for affordability.

TL;DR

Semaglutide patent expires on March 20, 2026, in India.
Over two dozen generic versions are set to launch soon after expiry.
Key companies preparing include Dr Reddy’s, Sun Pharma, and Zydus Lifesciences.
Nearly 50 generic versions are in development pipelines.
Current prices: Rybelsus Rs 6,900–9,000/month; Ozempic injection Rs 8,800–11,000; Wegovy Rs 11,850–26,050.
Generics expected to reduce costs by 60–70% initially and up to 80–90% over time.
Semaglutide treats type-2 diabetes and obesity via GLP-1 mechanism.
India’s anti-obesity drug market is Rs 3,000–3,500 crore, projected to grow eightfold by 2030.
Lower prices could improve access and enable earlier use in treatment pathways.
Experts call it a potential game-changer for diabetes and obesity management.